Knight Therapeutics Inc.

Knight Therapeutics Inc. Earnings Recaps

GUD.TO Health Care 3 recaps
Q1 2026 May 8, 2026

Knight Therapeutics shares jumped 15.7% following a record quarter driven by significantly higher revenues and adjusted EBITDA, with strong contributions from multiple portfolio acquisitions and new product launches exceeding expectations.

Key takeaways
  • Reported Q1 2026 revenues reached $148 million, up 68-69% year-over-year, fueled by the inclusion of Sumitomo and Paladin portfolios and growth in promoted products.
  • Adjusted EBITDA surged 130% to $28 million, reflecting improved gross margins and despite a 44% increase in operating expenses to support the expanded portfolio.
  • Adjusted gross margin improved slightly to 48% of revenues versus 47% a year ago, driven by higher sales volumes.
  • The company executed four product launches during the quarter and advanced regulatory approvals in Brazil, Argentina, and Mexico.
  • Net cash position strengthened to $69 million with ongoing debt repayments and a leverage ratio below 0.7x, underpinning financial flexibility.
Full recap
Q3 2025 Nov 7, 2025

Knight Therapeutics reported its strongest financial results to date for Q3 2025, achieving record revenues of $122.6 million, driven by significant growth from its oncology portfolio and strategic acquisitions.

Key takeaways
  • Adjusted revenue rose 34% year-over-year, with a notable contribution of $25 million from the Paladin and Sumitomo portfolios.
  • Adjusted EBITDA reached $49 million for the first nine months of 2025, demonstrating robust operational efficiency.
  • Successful launches of three new products in key markets, including JORNAY PM in Canada and MINJUVI in Argentina, bolstered the revenue stream.
  • Despite setbacks with TAVALISSE and Qelbree regulatory submissions, the company remains committed to addressing regulatory requirements.
  • Knight initiated a Normal Course Issuer Bid (NCIB) to repurchase up to 3 million shares, enhancing shareholder value.
Full recap
Q2 2025 Aug 8, 2025

Knight Therapeutics reported strong second-quarter results, achieving record adjusted revenues of CAD 108.5 million, a 15% year-over-year increase, alongside significant strategic business development activities.

Key takeaways
  • Adjusted EBITDA for Q2 2025 reached CAD 15.5 million, translating to CAD 0.16 per share, indicating strong operational performance.
  • The oncology and infectious disease portfolios saw robust growth, with revenue increases of 20% and 26% respectively, driven by new product launches and strategic transactions.
  • The company expanded its product offerings significantly, adding over 50 products through recent acquisitions, enhancing future growth potential.
  • Gross margin slightly declined to 46% due to product mix changes and severance costs from operational restructuring.
  • A new $50 million revolving credit facility has been secured, with plans to increase it to support ongoing acquisitions and growth initiatives in Canada and Latin America.
Full recap